Abstract

Statement on Measles-Mumps-Rubella-Varicella Vaccine: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Highlights

  • This statement reviews the one available measles-mumps-rubellavaricella (MMRV) vaccine, Priorix-TetraTM, GlaxoSmithKline (GSK) Inc., authorized for use in Canada, and makes recommendations for its use.Measles-mumps-rubella (MMR) vaccine has been available in Canada since the 1970s, and univalent varicella vaccine has been available since 1998

  • Please refer to the measles, mumps, rubella and varicella chapters in the most recent Canadian Immunization Guide (CIG) for the epidemiology of these individual diseases.(1) NACI has published a mumps vaccine update in response to mumps outbreaks, which affected previously immunized adolescents and adults from 2004 to 2007 in the United Kingdom, the United States and Canada.(2) NACI recommends a routine two-dose schedule for measles, and in 2007 extended the two-dose recommendation to include mumps.(1),(2) All provinces and territories in Canada currently provide two doses of MMR for children, with the first dose at 12 months and the second at either 18 months or 4 to 6 years of age

  • The commonly available laboratory tests (e.g., enzyme-linked immunosorbant assay (ELISA), immunofluorescence assay (IFA)) used to document immunity after wild-type varicella infection may not be sensitive enough to detect protective antibody levels, especially after a single dose of varicella-containing vaccine.(3)

Read more

Summary

Relevé des maladies transmissibles au Canada

Déclaration sur le vaccin contre la rougeole, la rubéole, les oreillons et la varicelle. Les recommandations d’utilisation et les autres renseignements qui figurent dans le présent document peuvent différer du contenu des monographies de produit établies par les fabricants du vaccin au Canada. Desai (Centre for Immunization and Respiratory Infectious Diseases), LCol (Dr.) James Anderson (Department of National Defence), Dr Ezzat Farzad (First National and Inuit Health Branch - Office of Community Medicine), Dr J. FarhangMehr (Centre de l’immunisation et des maladies respiratoires infectieuses), Dre S. Desai (Centre de l’immunisation et des maladies respiratoires infectieuses), Lcol (Dr) James Anderson (ministère de la Défense nationale), Dre Ezzat Farzad (Direction générale de la santé des Premières nations et des Inuits Bureau de la médecine communautaire), Dr J. Elliot (Centre de l’immunisation et des maladies respiratoires infectieuses), Dr P. Varughese (Centre de l’immunisation et des maladies respiratoires infectieuses), Dr R. Pless (Centre de l’immunisation et des maladies respiratoires infectieuses)

Introduction
Préparations vaccinales homologuées
Efficacy and Immunogenicity
Efficacité et immunogénicité
Recommended Usage
Schedule and Dosage
Calendrier et posologie
Primary Immunization
Route of Administration
Vaccination de rattrapage
Serologic Testing
Storage Requirements
Simultaneous Administration with Other Vaccines
Tests sérologiques
Adverse Reactions
Effets secondaires
Risk of Zoster after MMRV
Other Considerations
Autres considérations
Research Priorities for MMRV Vaccine
Priorités de recherche pour le vaccin RROV
Mumps strain Rubella strain Varicella strain Age group
Level of evidence based on research design
Findings
Niveaux de preuve fondés sur la méthodologoe de la recherche
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call